[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nrx Pharmaceuticals Inc (NRXP)

Nrx Pharmaceuticals Inc (NRXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 148,901
  • Shares Outstanding, K 36,229
  • Annual Sales, $ 1,230 K
  • Annual Income, $ -28,620 K
  • EBIT $ -17 M
  • EBITDA $ -17 M
  • 60-Month Beta 2.19
  • Price/Sales 115.93
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 183.88% (+5.74%)
  • Historical Volatility 75.50%
  • IV Percentile 48%
  • IV Rank 23.36%
  • IV High 734.57% on 02/13/26
  • IV Low 16.06% on 09/08/25
  • Expected Move (DTE 7) 0.21 (5.13%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 92
  • Volume Avg (30-Day) 363
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 15,234
  • Open Int (30-Day) 14,594
  • Expected Range 3.93 to 4.35

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.09
  • Number of Estimates 2
  • High Estimate $-0.05
  • Low Estimate $-0.13
  • Prior Year $-0.98
  • Growth Rate Est. (year over year) +90.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.10 +34.35%
on 06/24/26
4.25 -2.00%
on 07/08/26
+0.40 (+10.77%)
since 06/10/26
3-Month
2.18 +91.10%
on 04/13/26
5.05 -17.61%
on 06/02/26
+1.94 (+87.61%)
since 04/10/26
52-Week
1.62 +157.10%
on 03/09/26
5.05 -17.61%
on 06/02/26
+0.89 (+27.37%)
since 07/10/25

Most Recent Stories

More News
New to The Street Announces Broadcast of Show #759 on Bloomberg Television Across the U.S., MENA and Latin America tonight 630pm est.

FreeCast (NASDAQ:CAST), Big Sky Industrial (NASDAQ:BSIN), Virtuix Holdings (NASDAQ:VTIX), and Marco Polo Exchange's Steve Carlson Featuring Argentina's Capital Markets Highlight This Week's National Broadcast...

CAST : 2.84 (-16.72%)
RDZN : 1.1500 (-3.36%)
VTIX : 2.98 (-3.25%)
LTRN : 3.48 (+3.88%)
NRXP : 4.20 (+2.19%)
BSIN : 1.0900 (-2.68%)
DVLT : 0.3620 (-4.13%)
COCH : 0.6971 (-1.64%)
NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute

WILMINGTON, Del., June 25, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx” or the “Company”) today issued the following statement in response to recent public claims...

NRXP : 4.20 (+2.19%)
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System

First Zeta-navigated TMS treatments have begun at HOPE Therapeutics clinics in West Palm Beach and Sarasota, Florida, marking the transition from research deployment to active patient care AI-powered,...

NRXP : 4.20 (+2.19%)
ZETA SURGICAL® Announces Successful Treatment of First Patient with Zeta TMS Navigation System at HOPE Therapeutics

SARASOTA, Fla, and BOSTON , June 23, 2026 /PRNewswire/ -- ZETA SURGICAL and HOPE Therapeutics, an NRx Pharmaceuticals company (Nasdaq: NRXP), today announced the first patient treatment with the...

NRXP : 4.20 (+2.19%)
NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression

D-Cycloserine (DCS) has been reported to augment the effect of Transcranial Magnetic Stimulation (TMS) in remission from depression and suicidality in several published clinical studies. NRx Pharmaceuticals...

NRXP : 4.20 (+2.19%)
New to The Street broadcasts show #758 TODAY AT 6:30 PM ET on BLOOMBERG TELEVISION ACROSS THE UNITED STATES, LATIN AMERICA, AND MENA

Featured Interviews Include Aeries Technology (NASDAQ: AERT), Virtuix Holdings (NASDAQ: VTIX), and EmpowerLit; Sponsored Programming Supported by DataVault AI (NASDAQ: DVLT), IGC Pharma (NYSE American:...

IGC : 0.2705 (-3.05%)
VTIX : 2.98 (-3.25%)
AERT : 7.21 (+0.14%)
MDCX : 0.3990 (-5.56%)
NRXP : 4.20 (+2.19%)
DVLT : 0.3620 (-4.13%)
NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.

Osmind presented a retrospective comparative study of de-identified electronic health record data in a sample of 8,224 patients with treatment resistant depression treated with IV ketamine and 1,830 patients...

NRXP : 4.20 (+2.19%)
NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option

WILMINGTON, Del., June 04, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals” or the “Company”), a clinical-stage biopharmaceutical company, today announced...

NRXP : 4.20 (+2.19%)
NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock

WILMINGTON, Del., June 03, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals” or the “Company”), a clinical-stage biopharmaceutical company, today announced...

NRXP : 4.20 (+2.19%)
NRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

WILMINGTON, Del., June 02, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals” or the “Company”), a clinical-stage biopharmaceutical company, today announced...

NRXP : 4.20 (+2.19%)

Business Summary

NRX Pharmaceuticals Inc. is a patient-focused, clinical stage pharmaceutical company. It creates therapies to treat diseases where no medicines currently exist. NRX Pharmaceuticals Inc., formerly known as Big Rock Partners Acquisition Corp., is based in RADNOR, Pa.

See More

Key Turning Points

3rd Resistance Point 4.44
2nd Resistance Point 4.28
1st Resistance Point 4.20
Last Price 4.20
1st Support Level 3.96
2nd Support Level 3.80
3rd Support Level 3.72

See More

52-Week High 5.05
Last Price 4.20
Fibonacci 61.8% 3.74
Fibonacci 50% 3.34
Fibonacci 38.2% 2.93
52-Week Low 1.62

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.